(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 February 2014 (13.02.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/023957 A2

(51) International Patent Classification:
G01N 33/574 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/GB2013/052109

(22) International Filing Date:
7 August 2013 (07.08.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1214007.5 7 August 2012 (07.08.2012) GB

(71) Applicant: **SCANCELL LIMITED** [GB/GB]; Academic Clinical Oncology, City Hospital, Hucknall Road, Nottingham, Nottinghamshire NG5 1PB (GB).

(72) Inventors: **DURRANT, Linda Gillian**; c/o Scancell Limited, Academic Clinical Oncology, City Hospital Campus, Hucknall Road, Nottingham Nottinghamshire NG5 1PB (GB). **BRENTVILLE, Victoria Anne**; c/o Scancell Limited, Academic Clinical Oncology, City Hospital Campus, Hucknall Road, Nottingham Nottinghamshire NG5 1PB (GB). **METHERINGHAM, Rachel Louise**; c/o Scancell Limited, Academic Clinical Oncology, City Hospital Campus, Hucknall Road, Nottingham Nottinghamshire NG5 1PB (GB).

(74) Agent: **KILBURN & STRODE LLP**; 20 Red Lion Street, London, London, WC1R 4PJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2014/023957 A2

(54) Title: ANTI-TUMOUR RESPONSE TO MODIFIED SELF-EPITOPES

(57) Abstract: Anti-tumour immune responses to modified self-epitopes The present invention relates to the use of tumour-associated epitopes in medicine and in particular in the treatment of cancer. The epitopes stimulate an immune reaction against the tumour and have a modification selected from deimination of arginine to citrulline, nitration of tyrosine, oxidation of tryptophan and deamination of glutamine or asparagine. The invention also relates to nucleic acids comprising sequences that encode such epitopes for use in the treatment of cancer.